中国生物科技服务与华大基因签署战略合作协议
2月26日，中国生物科技服务（08037）发布公告，宣布与深圳华大基因科技有限公司签署了战略合作框架协议，并与鹏博（海南）硼中子医疗科技有限公司签署了投资意向书。框架协议的主要内容包括双方将在BNCT治疗合作、CAR-T治疗研究和应用、治疗后监测和疗效评估、肿瘤精准诊断与筛查等领域进行合作，目标是推动相关技术在中国的临床应用与学术推广。
此外，投资意向书中提到，投资人将对鹏博（海南）进行2000元至3000万元的投资，估值为4.5亿元。投资人将在鹏博（海南）完成首次公开发行前享有回购权、优先清算权和反稀释权等股东权益。此次合作及投资旨在提升鹏博（海南）的企业形象和资本基础，同时增强本公司在癌症治疗领域的服务能力。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10